GBIS - Global Innovative Systems, Inc. (fka GBIS)

[Ruellit]

Global Innovative Systems, Inc. (GBIS): Negotiations Opened with Consultants Which Specialize in FDA Procedures.

Global Innovative Systems, Inc. (GBIS): Negotiations Opened with
Consultants Which Specialize in FDA Procedures.

LAS VEGAS, Mar 13, 2002 /PRNewswire-FirstCall via COMTEX/ -- The directors of Global Innovative Systems, Inc. (OTC Bulletin Board: GBIS), a Nevada corporation, announced that the Company has entered into negotiations with a US-based consulting group which specialize in the procedures necessary for medical device applications to the Food and Drug Administration. The Company
believes that the consulting group's specific experience will supplement the existing expertise of Energy Medicine Developments management group as the Company prepares for its third, double blind, placebo controlled clinical trial into the symptomatic relief of multiple sclerosis.

The Enermed Therapy is licensed by Health Canada to provide non-invasive symptomatic relief to people with multiple sclerosis and/or migraine headaches. The effectiveness of the Enermed Therapy has been evaluated through controlled clinical trials. Additionally, a company survey mailed to Enermed patients one
to fifteen months after they received their individually programmed Enermed devices indicated that the large majority of people using the device experienced improvement in their condition.

An estimated 13 to 17 billion dollars are lost in the United States each year in direct and indirect costs associated with migraine headaches, including such items as lost wages and reduced productivity. According to a study presented at the American Academy of Neurology, approximately half of the estimated 28 million migraine sufferers in the United States have given up on conventional medical treatments, and the majority (64%) of those who do seek medical help are dissatisfied with their care. Individuals seeking relief from chronic debilitating headaches are more likely than ever to turn to alternative, non-drug therapies such as the Enermed.

It is estimated that there are 500,000 MS sufferers in the United States and up to 2 million worldwide. The National Multiple Sclerosis Society estimates that direct and indirect costs associated with MS exceed 9 billion dollars annually.
Due to the relatively low effect rate of traditional MS medications, many MS patients are looking to alternative therapies to alleviate their symptoms.

For more information on the Enermed Therapy for the symptomatic relief of multiple sclerosis and/or migraine headaches visit the Company's website at http://www.enermed.com, to schedule an appointment call 1-866 ENERMED, or for information on Investor Relations contact Yorkville Capital Partners at [phone].

Certain of these statements contained in the press release may be deemed forward-looking statements. Such statements, and other matters addressed in this press release, involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from these statements and
matters are the risks and other factors detailed, from time to time, in the Company's reports with Securities and Exchange Commissions, including, but not limited to, the Company's Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q.


Muell <g>